News & Articles

New service reduces project time from months to weeks for biopharma customers

Hear from a microbiology expert at Yale School of Public Health about a simplified PCR test for COVID-19

The Allplex SARS-CoV-2 Master Assay can detect a total of 10 targets including four coronavirus genes

Seegene’s new product filters COVID-19 and variants during primary PCR testing in 1 hr 55 min

Dr. Boye Schnack Nielsen shares tips for running successful in situ hybridization assays as he provides insights on how RNA detection methods have evolved over time

The antigen test is used to detect the nucleocapsid protein antigen in SARS-CoV-2

m2p-labs, BioLector family of products acquired by Beckman Coulter Life Sciences in 2020

Explore topics from micro- and nanoscale LC-MS analysis to NGS sample quality control, EEM and A-TEEM spectroscopy, and oligonucleotide analysis

Seegene can produce 300,000 variant diagnostic test kits, capable of testing 30 million people every month

Explore the latest science and technology advancements in regenerative medicine, COVID-19 diagnostic testing, cardiovascular treatments, point-of-care and more

Highly complementary cell counting and analysis capabilities bolster preclinical portfolio and enhance QA/QC capabilities in cell and gene therapy and biologics manufacturing

The Simplexa™ SARS-CoV-2 Variants Direct assay aims to enable detection of four mutations associated with virus variants without requiring upfront RNA extraction

The availability of an International Standard (IS) for antibodies facilitates the standardization of SARS-CoV-2 serological methods

Platform poised to be first CLIA-waived CRISPR-based, point-of-care COVID-19 device with central-lab performance, developed in collaboration with Sherlock Biosciences

Explore topics from live-cell analysis, in situ hybridization, cancer therapeutics, cell imaging, and much more

For a chance to win a $500/£400/450€ Amazon Gift Card, cast your vote for the new products which have made the most difference to clinical diagnostics

FDA Breakthrough Device Designation for Sepsis, Joint & Implant Infections, Infective Endocarditis, Bacterial Meningitis